Due to COVID-19 first half results are more representative of underlying performance than Q2, sales growth of 6% (cc1, +3% USD) and core¹ operating income growth of 19% (cc, +14% USD):Innovative Medicines grew sales 7% (cc, +5% USD) and core operating…
Daptomycin is an antibacterial medicine used to treat adult patients with complicated skin and skin structure infections 1Daptomycin can be used to treat patients with MRSA or “superbug” infections2Introduction of Daptomycin further enhances Sandoz ind…
Sandoz to provide six injectable medicines used in acute care settings to help ensure supply reliability for optimal patient careSecuring reliable supply of and access to these high-quality medicines will help ensure fewer shortages and interruptions f…
Sandoz evaluating next steps, including potential appeal to US Supreme CourtRuling continues to prevent launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases Sandoz remains deeply comm…
Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made Novartis remains committed to ongoing research and development for COVID-19 Supply of hydroxychloroquine (HCQ) from Novartis will c…
Sandoz is first and only company offering complete range of dosing options in several European markets*, with 2 mg capsule allowing for fine dose titrationSandoz 2 mg slow-release capsule offers simplified once-daily treatment protocol that may reduce …
Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz:Key growth drivers include Entresto USD 569 million (+62% cc), Zolgensma USD 170 million, Cosentyx USD 930 million (…
Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz:Key growth drivers include Entresto USD 569 million (+62% cc), Zolgensma USD 170 million, Cosentyx USD 930 million (…
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial is designed and implemented quickly to address the n…
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial is designed and implemented quickly to address the n…